HomeComparePPRW vs JNJ

PPRW vs JNJ: Dividend Comparison 2026

PPRW yields 1000000.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PPRW wins by $4.7683925249533696e+36M in total portfolio value
10 years
PPRW
PPRW
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full PPRW calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — PPRW vs JNJ

📍 PPRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPPRWJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PPRW + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PPRW pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PPRW
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, PPRW beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PPRW + JNJ for your $10,000?

PPRW: 50%JNJ: 50%
100% JNJ50/50100% PPRW
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PPRW
No analyst data
Altman Z
-0.3
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PPRW buys
0
JNJ buys
0
No recent congressional trades found for PPRW or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPPRWJNJ
Forward yield1000000.00%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$4.7683925249533696e+36M$20.0K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$827.78
Total dividends collected$4.7683311610149396e+36M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PPRW vs JNJ ($10,000, DRIP)

YearPPRW PortfolioPPRW Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,676$355.77+$100.00MPPRW
2$934,786,450,701$934,679,439,252.34$11,407$389.39+$934786.44MPPRW
3$8,165,787,108,578,292$8,164,786,887,076,042.00$12,198$426.53+$8165787108.57MPPRW
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$13,056$467.62+$66665884190957.63MPPRW
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$13,987$513.12+$508662171058048128.00MPPRW
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$14,998$563.56+$3.62723524842849e+21MPPRW
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$16,098$619.52+$2.417368115915061e+25MPPRW
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$17,295$681.69+$1.5056740286145463e+29MPPRW
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$18,599$750.82+$8.764771002818475e+32MPPRW
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$20,022$827.78+$4.7683925249533696e+36MPPRW

PPRW vs JNJ: Complete Analysis 2026

PPRWStock

Premier Power Renewable Energy, Inc., through its wholly owned subsidiaries, engages in the design, development, and integration of ground mount and rooftop solar energy systems for commercial, industrial, residential, agricultural, and equity fund customers in North America, Europe, and Asia. It also provides a range of installation services to its solar energy customers, including design, engineering, procurement, permitting, construction, grid connection, warranty, system monitoring, and maintenance services. In addition, the company distributes solar energy system components comprising racking, wiring, inverters, solar modules, and other related components to smaller solar developers and integrators. Premier Power Renewable Energy, Inc. was founded in 2001 and is headquartered in El Dorado Hills, California.

Full PPRW Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this PPRW vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PPRW vs SCHDPPRW vs JEPIPPRW vs OPPRW vs KOPPRW vs MAINPPRW vs ABBVPPRW vs MRKPPRW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.